Literature DB >> 28164667

Albuminuria is Suggested as a Potential Health Screening Biomarker for Senior Citizens and General Population with Hypertension or Diabetes in China.

Dongmei Gu, Pengcheng Xu, Yuhua Yuan, Hongwei Fu.   

Abstract

BACKGROUND: To evaluate the possibility of albuminuria as a screening biomarker for seniors or general population with hypertension and diabetes.
METHODS: 478 health check-up individuals were enrolled. Albumin to creatinine ratio (ACR) was calculated by testing urinary albumin and creatinine of spot urine sample. Each urine sample was also analyzed by the routine urine test in parallel with ACR. Potential risk factors associated with the presence of albuminuria were analyzed using independent t-test or chi-square test.
RESULTS: The total prevalence of albuminuria was 11.9%, and women had a higher positive rate (14.0%) than men (10.6%). Ageing, fasting plasma glucose, and systolic blood pressure were significantly associated with the presence of albuminuria. Individuals are highly probable to have albuminuria when their routine urine test shows positive of urea glucose, red blood cells or urea protein.
CONCLUSIONS: Albuminuria should be suggested as a potential health screening biomarker in senior citizens and general population with hypertension and diabetes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28164667     DOI: 10.7754/Clin.Lab.2016.160212

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  2 in total

1.  The Multi-Institutional Health Screening Records Database of South Korea: Description and Evaluation of Its Characteristics.

Authors:  Yunha Noh; Han Eol Jeong; Hye Jun Kim; Hanju Ko; Eun Hee Nah; Ju Young Shin
Journal:  Yonsei Med J       Date:  2019-12       Impact factor: 2.759

2.  Clinical significance of serum interleukin-8 and soluble tumor necrosis factor-like weak inducer of apoptosis levels in patients with diabetic nephropathy.

Authors:  Shu-Yan Liu; Jie Chen; Yong-Feng Li
Journal:  J Diabetes Investig       Date:  2018-03-26       Impact factor: 4.232

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.